Format

Send to

Choose Destination
Sci Rep. 2018 Aug 23;8(1):12675. doi: 10.1038/s41598-018-31027-y.

A response prediction model for taxane, cisplatin, and 5-fluorouracil chemotherapy in hypopharyngeal carcinoma.

Zhong Q1,2,3, Fang J4,5,6, Huang Z1,2,3, Yang Y1,2,3, Lian M1,2,3, Liu H7, Zhang Y8, Ye J9, Hui X10, Wang Y10, Ying Y11, Zhang Q12, Cheng Y13.

Author information

1
Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
2
Beijing Institute of Otolaryngology, Beijing, China.
3
Key Laboratory of Otolaryngology Head and Neck Surgery, Capital Medical University, Ministry of Education, Beijing, China.
4
Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China. fangjugao19651110@163.com.
5
Beijing Institute of Otolaryngology, Beijing, China. fangjugao19651110@163.com.
6
Key Laboratory of Otolaryngology Head and Neck Surgery, Capital Medical University, Ministry of Education, Beijing, China. fangjugao19651110@163.com.
7
Beijing Key Laboratory of Head and Neck Molecular Diagnostic Pathology, Beijing, 100730, China.
8
Department of Urology, The Second Affiliated Hospital of Jinan University, Shenzhen People's Hospital, Shenzhen, Guangdong, China.
9
Neurontechnology, Shenzhen, Guangdong, China.
10
Department of Cell Biology and Medical Genetics, Shenzhen University Medical School, Shenzhen, 518060, China.
11
Department of Physiology, School of Basic Medical Sciences, Shenzhen University Health Sciences Center, Shenzhen, 518060, China.
12
Neurontechnology, Shenzhen, Guangdong, China. zhqingfu@gmail.com.
13
Department of Urology, The Second Affiliated Hospital of Jinan University, Shenzhen People's Hospital, Shenzhen, Guangdong, China. chengyingduan@gmail.com.

Abstract

Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide. The five-year survival rate of HNSCC has not improved even with major technological advancements in surgery and chemotherapy. Currently, docetaxel, cisplatin, and 5-fluoruracil (TPF) treatment has been the most popular chemotherapy method for HNSCC; but only a small percentage of HNSCC patients exhibit a good response to TPF treatment. Unfortunately, at present, no reasonably effective prediction model exists to assist clinicians with patient treatment. For this reason, patients have no other alternative but to risk neoadjuvant chemotherapy in order to determine their response to TPF. In this study, we analyzed the gene expression profile in TPF-sensitive and non-sensitive patient samples. We identified a gene expression signature between these two groups. We further chose 10 genes and trained a support vector machine (SVM) model. This model has 88.3% sensitivity and 88.9% specificity to predict the response to TPF treatment in our patients. In addition, four more TPF responsive and four more TPF non-sensitive patient samples were used for further validation. This SVM model has been proven to achieve approximately 75.0% sensitivity and 100% specificity to predict TPF response in new patients. This suggests that our 10-genes SVM prediction model has the potential to assist clinicians to personalize treatment for HNSCC patients.

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center